Excuse me. Efraim?
DR. SHEK: I want to just note for the record that since my employer has an interest in this discussion, I am recusing myself from active participation in this session. But with your permission, I'll continue sitting here because it's a packed house.
DR. KIBBE: Thank you, Efraim.
DR. CONNER: I'm sure you're all getting tired of seeing my face, especially going on and on about trying to tell people the basics of bioequivalence which I'm starting, I think, after these many years, to get tired of trying to explain to people and still hearing a lot of misconceptions about it.
I'd like to start off, though, on the part of the FDA by saying another vote of thanks to the people that came during the public comment period. I know that they took time out from their busy schedules, sometimes at a lot of expense to themselves to come and give their opinions and concerns, and I'd like to say that we at the FDA take those concerns very seriously and they're of great value to us. And so thank you again, if any of you